PureTech Health plc (NASDAQ:PRTC) Sees Large Decline in Short Interest

PureTech Health plc (NASDAQ:PRTC - Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 9,700 shares, a decrease of 61.5% from the March 15th total of 25,200 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 4,400 shares, the short-interest ratio is presently 2.2 days.

Hedge Funds Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Millennium Management LLC purchased a new position in PureTech Health plc (NASDAQ:PRTC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned 0.19% of PureTech Health as of its most recent filing with the Securities and Exchange Commission (SEC). 0.04% of the stock is owned by institutional investors.

PureTech Health Stock Up 1.1 %

Shares of PRTC traded up $0.18 during mid-day trading on Friday, hitting $16.93. 1,302 shares of the company's stock were exchanged, compared to its average volume of 4,642. The stock's 50-day simple moving average is $17.65 and its 200-day simple moving average is $19.27. PureTech Health has a 52 week low of $13.30 and a 52 week high of $32.98.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.